



ANNOUNCEMENT

CHANGE IN CHIEF FINANCIAL OFFICER AND COMPANY SECRETARY

21st December 2010, Melbourne Australia: Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that it has appointed Mr Mark Cansdale as Chief Financial Officer (CFO) and Company Secretary. Mark takes over from Mr Aaron Finlay who has decided to leave Mayne Pharma to pursue other career interests.

Mark is a Chartered Accountant and will bring more than 20 years experience to the role. Mark was formerly the CFO and Company Secretary at McMillan Shakespeare Limited and prior to that, Vision Systems Limited. Mark has extensive experience in the areas of business development, mergers and acquisitions, corporate strategy, tax, financial planning and analysis, risk management, treasury and investor relations. Prior to joining Vision Systems in 2002, Mark held senior finance positions in the insurance and financial services industry at Norwich Union Australia and KPMG.

Mayne Pharma's CEO, Dr Roger Aston said "The Board and I would like to thank Aaron for his commitment and support over the past five years and wish him every success in the future. Aaron was closely involved in the development of Halcygen Pharmaceuticals (now Mayne Pharma) and in the acquisition of Mayne Pharma International Pty Ltd from Hospira Inc. Mark will be a great addition to the Mayne Pharma team and I look forward to building the business further with Mark's support."

-ENDS-

For Further information contact:

Dr Roger Aston 0402 762 204, r.aston@halcygen.com

Lisa Pendlebury 0419 548 434, lisa.pendlebury@maynepharma.com

Mayne Pharma Profile:

Mayne Pharma Group Limited (Mayne Pharma) is an Australian specialist pharmaceutical company with an intellectual property portfolio built around the optimisation and delivery of oral dosage form drugs.

Mayne Pharma has a long and successful history of developing and commercializing improved pharmaceuticals and has launched and marketed numerous products through partnerships with licensees in various countries around the world. Mayne Pharma focuses on delivering to patients improved versions of existing drugs in order to advance safety, efficacy or ease of administration.

A technology driven company, Mayne Pharma has a significant product portfolio and pipeline, global reach through distribution partners in Australia, USA, Europe and Asia and a manufacturing facility based in Salisbury, South Australia that employs over 150 people on a 32 acre site. The facility also undertakes the manufacture of products under contract for third parties to TGA, FDA and EU regulatory guidelines.